Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

4 reports from 3 outlets in 1 language · first reported 2026-09-30 20:01 UTC · updated 2026-10-01 11:30 UTC · JSON

Reports

1. Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Riskfinanznachrichten.de · en · 2026-10-01 11:30 UTC
2. Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD RiskGlobeNewswire — public companies · en · 2026-10-01 11:00 UTC
3. Monte Rosa Set To Report MRT-8102 Phase 1 Data In Cardiovascular Risk Study Today; Stock Uprttnews.com · en · 2026-10-01 04:50 UTC
4. Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease RiskGlobeNewswire — public companies · en · 2026-09-30 20:01 UTC